Kalvista Pharmaceuticals Inc reports results for the quarter ended in January - Earnings Summary

Kalvista Pharmaceuticals

11/03/2024 13:31

* Kalvista Pharmaceuticals Inc  KALV.OQ  reported a
quarterly
adjusted loss of 84 cents​​ per share for the quarter ended in
January, lower than the same quarter last year, when the company
reported EPS of -75 cents.  The mean expectation of six analysts
for the quarter was for a loss of 77 cents per share. Wall
Street expected results to range from -87 cents to -69 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kalvista Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 84 cents​.
    * The company reported a quarterly loss of $29.03 million.
    * Kalvista Pharmaceuticals Inc shares had risen by 17.2%
this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.9%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is  "buy."

Wall Street's median 12-month price target for Kalvista
Pharmaceuticals Inc is $35.00 
This summary was machine generated from LSEG data March 11 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 31 2024      -0.77          -0.84          Missed
 Oct. 31 2023      -0.79          -0.80          Missed
 Jul. 31 2023      -0.86          -0.74          Beat
 Apr. 30 2023      -0.94          -0.77          Beat